Piper Sandler maintains Overweight rating on Skye Bioscience stock ahead of trial data

Piper Sandler and JMP Securities reiterated bullish ratings on Skye Bioscience (SKYE) ahead of anticipated late Q3/early Q4 Phase IIa data for its obesity treatment, nimacimab, with Piper Sandler expecting at least 5% placebo-adjusted weight loss and a favorable safety profile. Despite a recent Q2 net loss attributed to increased R&D, the company maintains strong financial health, bolstering analyst confidence alongside promising preclinical and Phase 1b results for its nimacimab pipeline.

Analysis

Skye Bioscience (SKYE) is positioned for a significant near-term catalyst, with both Piper Sandler and JMP Securities reiterating bullish ratings ahead of its upcoming clinical trial results. The primary focus is the Phase IIa CBeyond data for its obesity treatment, nimacimab, expected in late Q3 or early Q4. Analyst expectations are specific, with Piper Sandler forecasting at least 5% placebo-adjusted weight loss and a superior safety profile, including reduced gastrointestinal toxicity and no neuropsychiatric adverse events. This positive outlook is supported by a strong financial position, as the company holds more cash than debt, providing flexibility despite a Q2 2025 net loss of $17.6 million, which was attributed to strategic increases in R&D spending. Further de-risking evidence is provided by positive Phase 1b safety data and promising preclinical results showing over 40% weight loss in mice when nimacimab was combined with tirzepatide. The stock's 17.25% price return over the past six months reflects growing investor anticipation for these pivotal results, with Piper Sandler and JMP maintaining price targets of $20.00 and $15.00, respectively.

Key Decisions for Investors

• Given the strong analyst consensus and sound financial footing, investors with a high risk tolerance may consider positioning ahead of the late Q3/early Q4 Phase IIa data release, which serves as a major near-term catalyst.
• Investors must recognize the binary nature of the upcoming clinical trial results, as a failure to meet the benchmark of at least 5% placebo-adjusted weight loss or the emergence of adverse safety events could lead to significant downside volatility.
• Long-term value will depend on nimacimab's differentiation in the competitive obesity market, so investors should evaluate the upcoming data for its potential as a combination therapy and its safety profile relative to existing treatments.